MA42624A - Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive - Google Patents
Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitiveInfo
- Publication number
- MA42624A MA42624A MA042624A MA42624A MA42624A MA 42624 A MA42624 A MA 42624A MA 042624 A MA042624 A MA 042624A MA 42624 A MA42624 A MA 42624A MA 42624 A MA42624 A MA 42624A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- treatment methods
- benzodiazepine derivatives
- cognitive deficiency
- cognitive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562182336P | 2015-06-19 | 2015-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42624A true MA42624A (fr) | 2021-04-28 |
Family
ID=57546444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042624A MA42624A (fr) | 2015-06-19 | 2016-06-17 | Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10815242B2 (https=) |
| EP (1) | EP3310785B1 (https=) |
| JP (2) | JP6987384B2 (https=) |
| CN (2) | CN113264939A (https=) |
| AU (2) | AU2016279052A1 (https=) |
| CA (1) | CA2990004C (https=) |
| EA (1) | EA036844B1 (https=) |
| IL (1) | IL256354B (https=) |
| MA (1) | MA42624A (https=) |
| MX (2) | MX392119B (https=) |
| WO (1) | WO2016205739A1 (https=) |
| ZA (1) | ZA201800360B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3083569B1 (en) | 2013-12-20 | 2022-01-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| JP6987384B2 (ja) | 2015-06-19 | 2021-12-22 | エージンバイオ， インコーポレイテッド | ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 |
| US20180170941A1 (en) * | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11414425B2 (en) | 2018-06-19 | 2022-08-16 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US20220105106A1 (en) * | 2019-02-13 | 2022-04-07 | Centre For Addiction And Mental Health | Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors |
| IL294031A (en) * | 2019-12-19 | 2022-08-01 | Agenebio Inc | History of benzodiazepines, preparations and methods for the treatment of cognitive impairment |
| JP2023534190A (ja) * | 2020-07-10 | 2023-08-08 | エージンバイオ， インコーポレイテッド | ＧＡＢＡＡα５アゴニストの多形および認知障害の処置において使用する方法 |
| WO2024039886A1 (en) | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2024196801A1 (en) * | 2023-03-17 | 2024-09-26 | LAPKO INC, dba AFECTA PHARMACEUTICALS | Methods for treating aberrant behavior and motor activity |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| ES413944A1 (es) | 1972-04-20 | 1976-06-01 | Merz & Co | Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5. |
| NL7605526A (nl) | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| CA2000786C (en) | 1988-11-07 | 1999-01-26 | Janssen Pharmaceutica, Naamloze Vennootschap | 3-piperidinyl-1,2-benzisoxazoles |
| US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| DE58905637D1 (de) | 1989-04-14 | 1993-10-21 | Merz & Co Gmbh & Co | Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie. |
| ES2076253T3 (es) | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| ES2131506T3 (es) | 1990-09-21 | 1999-08-01 | Rohm & Haas | Dihidropiridacinonas y piridacinonas como fungicidas. |
| US5190951A (en) | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| WO1992020682A1 (en) | 1991-05-24 | 1992-11-26 | E.I. Du Pont De Nemours And Company | Arthropodicidal anilides |
| US5106856A (en) | 1991-06-07 | 1992-04-21 | Hoechst-Roussel Pharmaceuticals Inc. | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
| TW201311B (https=) | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| JP4099224B2 (ja) | 1994-03-02 | 2008-06-11 | ナームローゼ・フエンノートチヤツプ・オルガノン | 舌下又はバッカル医薬組成物 |
| US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
| AU1041599A (en) | 1997-11-13 | 1999-06-07 | Jose Luis Castro Pineiro | Therapeutic uses of triazolo-pyridazine derivatives |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| WO2000027849A2 (en) | 1998-11-12 | 2000-05-18 | Merck & Co., Inc. | Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same |
| WO2000051985A1 (en) | 1999-03-03 | 2000-09-08 | Eisai Co., Ltd. | Fluorides of 4-substituted piperidine derivatives |
| GB9911804D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911803D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911802D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9929569D0 (en) | 1999-12-14 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| TWI239333B (en) | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| WO2002069948A1 (en) | 2001-03-01 | 2002-09-12 | Pfizer Products Inc. | Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| US20050071088A1 (en) | 2001-08-13 | 2005-03-31 | Landfield Philip W | Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment |
| EP1471909A4 (en) | 2002-01-16 | 2007-07-25 | Endo Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
| GB0218876D0 (en) | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| CA2495285A1 (en) | 2002-08-13 | 2004-02-19 | Merck Sharp & Dohme Limited | Phenylpyridazine derivatives as ligands for gaba receptors |
| US7635709B2 (en) | 2002-09-26 | 2009-12-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction |
| KR100777904B1 (ko) | 2002-10-24 | 2007-11-28 | 메르츠 파마 게엠베하 운트 코. 카가아 | 1-아미노시클로헥산 유도체 및 아세틸콜린에스테라제 저해제를 포함하는 약학적 제품 및 이를 이용한 복합 치료 |
| US20040191803A1 (en) | 2002-11-22 | 2004-09-30 | Michela Gallagher | Target for therapy of cognitive impairment |
| CN1870984A (zh) | 2003-10-22 | 2006-11-29 | 莫茨药物股份两合公司 | 1－氨基环己烷衍生物用于调节淀粉样病变中原纤维生成Aβ肽的沉积的用途 |
| US20060079582A1 (en) | 2004-09-23 | 2006-04-13 | Jeffrey Jonas | Memantine for the treatment of childhood behavioral disorders |
| WO2006040038A1 (en) * | 2004-10-12 | 2006-04-20 | F.Hoffmann-La Roche Ag | Imidazo [1, 5-a]triazolo[1, 5-d]benzodiazepine derivatives for the treatment of cognitive disorders |
| ES2399439T3 (es) * | 2004-10-20 | 2013-04-01 | F. Hoffmann-La Roche Ag | Derivados de imidazo-benzodiazepina |
| AU2005299031B2 (en) | 2004-10-20 | 2011-11-10 | F. Hoffmann-La Roche Ag | Halogen substituted benzodiazepine derivatives |
| BRPI0515800A (pt) | 2004-12-14 | 2008-08-05 | Hoffmann La Roche | imidazo-benzodiazepinas tetracìclicas como moduladores de receptores de gaba |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| EP1888594A2 (en) | 2005-05-16 | 2008-02-20 | Wisys Technology Foundation, Inc. | Gabaergic agents to treat memory deficits |
| EP1924712B1 (en) | 2005-08-03 | 2018-10-03 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| US8510055B2 (en) | 2005-08-03 | 2013-08-13 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| KR101009860B1 (ko) * | 2005-10-11 | 2011-01-19 | 에프. 호프만-라 로슈 아게 | 이미다조 벤조다이아제핀 유도체 |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| WO2010014220A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| WO2010036553A1 (en) | 2008-09-24 | 2010-04-01 | E. I. Du Pont De Nemours And Company | Fungicidal pyridazines |
| BRPI0920515B1 (pt) | 2008-09-25 | 2018-03-20 | Vive Nano, Inc. | Composição compreendendo nanopartícula de polímero e composto ativo agrícola |
| US8344028B2 (en) | 2009-04-17 | 2013-01-01 | Xenoport, Inc. | Gamma-amino-butyric acid derivatives as GABAB receptor ligands |
| US8853219B2 (en) | 2010-01-11 | 2014-10-07 | Neurosolis, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| MX341471B (es) * | 2010-11-05 | 2016-08-22 | Hoffmann La Roche | Uso de compuestos farmaceuticos activos para el tratamiento de estados patologicos del sistema nervioso central. |
| WO2012068149A1 (en) | 2010-11-15 | 2012-05-24 | Agenebio, Inc. | Benzodiazepine derivatives, compositions and methods for treating cognitive impairment |
| EP3034079B1 (en) | 2010-11-15 | 2018-01-10 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
| WO2012161133A1 (ja) | 2011-05-20 | 2012-11-29 | 日産化学工業株式会社 | 置換ピリダジン化合物及び農園芸用殺菌剤 |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| AU2013312240A1 (en) | 2012-09-10 | 2015-03-19 | Ophirex Inc. | Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade |
| EP3083569B1 (en) | 2013-12-20 | 2022-01-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| JP6987384B2 (ja) | 2015-06-19 | 2021-12-22 | エージンバイオ， インコーポレイテッド | ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN108567787A (zh) | 2017-03-10 | 2018-09-25 | 辛衍雪 | 一种治疗慢性阻塞性肺病的药物组合物 |
| US11414425B2 (en) | 2018-06-19 | 2022-08-16 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
-
2016
- 2016-06-17 JP JP2017565726A patent/JP6987384B2/ja active Active
- 2016-06-17 MX MX2020013374A patent/MX392119B/es unknown
- 2016-06-17 CN CN202110582826.3A patent/CN113264939A/zh active Pending
- 2016-06-17 CN CN201680042224.6A patent/CN108026107B/zh active Active
- 2016-06-17 AU AU2016279052A patent/AU2016279052A1/en not_active Abandoned
- 2016-06-17 US US15/736,697 patent/US10815242B2/en active Active
- 2016-06-17 EA EA201890090A patent/EA036844B1/ru not_active IP Right Cessation
- 2016-06-17 CA CA2990004A patent/CA2990004C/en active Active
- 2016-06-17 MX MX2017015752A patent/MX384734B/es unknown
- 2016-06-17 MA MA042624A patent/MA42624A/fr unknown
- 2016-06-17 EP EP16812577.1A patent/EP3310785B1/en active Active
- 2016-06-17 WO PCT/US2016/038224 patent/WO2016205739A1/en not_active Ceased
- 2016-06-17 IL IL256354A patent/IL256354B/en unknown
-
2018
- 2018-01-18 ZA ZA2018/00360A patent/ZA201800360B/en unknown
-
2020
- 2020-09-22 US US17/028,917 patent/US11312721B2/en active Active
-
2021
- 2021-01-13 AU AU2021200164A patent/AU2021200164B2/en active Active
- 2021-06-24 JP JP2021105189A patent/JP2021152071A/ja not_active Withdrawn
-
2022
- 2022-02-04 US US17/592,679 patent/US12024525B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021152071A (ja) | 2021-09-30 |
| MX384734B (es) | 2025-03-14 |
| EA201890090A1 (ru) | 2018-09-28 |
| JP6987384B2 (ja) | 2021-12-22 |
| WO2016205739A1 (en) | 2016-12-22 |
| US11312721B2 (en) | 2022-04-26 |
| US20210009602A1 (en) | 2021-01-14 |
| JP2018521034A (ja) | 2018-08-02 |
| AU2016279052A1 (en) | 2018-02-15 |
| MX2020013374A (es) | 2022-05-06 |
| AU2021200164B2 (en) | 2022-09-08 |
| HK1254362A1 (zh) | 2019-07-19 |
| EP3310785A4 (en) | 2018-12-26 |
| IL256354A (en) | 2018-02-28 |
| US10815242B2 (en) | 2020-10-27 |
| CN108026107B (zh) | 2021-07-30 |
| ZA201800360B (en) | 2023-03-29 |
| EP3310785A1 (en) | 2018-04-25 |
| IL256354B (en) | 2022-09-01 |
| CN113264939A (zh) | 2021-08-17 |
| AU2021200164A1 (en) | 2021-03-18 |
| CA2990004C (en) | 2024-04-23 |
| US20220274996A1 (en) | 2022-09-01 |
| CN108026107A (zh) | 2018-05-11 |
| MX392119B (es) | 2025-03-11 |
| EP3310785B1 (en) | 2024-11-20 |
| EA036844B1 (ru) | 2020-12-28 |
| US20190055258A1 (en) | 2019-02-21 |
| MX2017015752A (es) | 2018-04-13 |
| US12024525B2 (en) | 2024-07-02 |
| CA2990004A1 (en) | 2016-12-22 |
| NZ739092A (en) | 2024-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3555100A4 (en) | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | |
| MA42624A (fr) | Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| MA45188A (fr) | Oligonucléotides, compositions et méthodes associées | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| EP3390666A4 (en) | COMPOSITIONS AND METHODS OF TREATING NURSE DISEASES | |
| EP3436018A4 (en) | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS AND METHOD FOR TREATING THEREOF | |
| PL3580211T3 (pl) | 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu | |
| PL3377516T3 (pl) | Kompozycja do leczenia nowotworu | |
| EP3313530A4 (en) | 4,6-PYRIMIDINYLENE DERIVATIVES AND USE THEREOF | |
| BR112017018413A2 (pt) | tratamento de pancreatite | |
| EP3679063A4 (en) | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OR PREVENTION OF HER-CONTROLLED DRUG-RESISTANT CANCER | |
| MA54254A (fr) | Dérivés de benzodiazépine cytotoxique | |
| ZA201605027B (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| LT3390390T (lt) | Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui | |
| PT3265087T (pt) | Método de tratamento com tradipitant | |
| EP3373962A4 (en) | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCER DISEASES | |
| EP3457851A4 (en) | DERIVATIVES OF SOBETIROM | |
| LT3353177T (lt) | Tricikliniai heterociklai, skirti vėžio gydymui | |
| CL2015000926A1 (es) | Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios. | |
| LT3377094T (lt) | Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui | |
| EP3500257A4 (en) | KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | |
| EP3686204A4 (en) | THIENODIAZEPIN DERIVATIVES AND THEIR USES | |
| DK3302573T3 (da) | Sammensætning til behandlingen af hjernelæsioner | |
| EP3352729A4 (en) | METHOD AND COMPOSITIONS FOR SKIN TREATMENT |